Clinical effect of entecavir combined with probiotics on treatment of patients with hepatitis B cirrhosis

doi:10.12092/j.issn.1009-2501.2018.07.012

Abstract

Abstract:

AIM: To observe the clinical efficacy of nucleoside antiviral drugs (entecavir) combined with probiotics (Bifid triple viable capsules) in the treatment of patients with hepatitis B cirrhosis. METHODS: One hundred and sixty patients with cirrhosis caused by hepatitis B virus infection admitted to our department of hepatology from July 2014 to January 2017 were randomly divided into control group and observation group, with 80 cases in each group. The two groups were treated with basic liver protection, and the control group was treated with entecavir 0.5 mg/times/day orally, while the observation group was given extra Bifidobacterium triple viable capsules 2 times a day, 2-4 capsules per time. All patients received continuous treatment for 6 months, during which the clinical signs, the liver region B ultrasound, liver function, the liver fiber 4 items and the peripheral blood T cell subgroup level of two groups were observed. RESULTS: Compared with before treatment, ALT, AST, TBIL, blood ammonia and endotoxin, liver fibrosis and immune response index, the diameter of portal vein and spleen thickness were significantly improved after treatment (P＜0.05); also, compared with control group, those indexes of the observation group improved more significantly (P＜0.05); comparison of the complications after treatment had no significant difference. CONCLUSION: Entecavir combined with Bifidobacterium triple viable capsule can improve the intestinal homeostasis, further reduce liver fibrosis and improve liver function in patients with viral hepatitis B cirrhosis.

Key words: entecavir, probiotics, clinical efficacy, hepatitis B

CLC Number:

ZENG Chuanli, HU Airong, HU Yaoren, YUAN Gang, ZHU Dedong, SHI Xiaojun. Clinical effect of entecavir combined with probiotics on treatment of patients with hepatitis B cirrhosis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 796-801.

References

［1］陈海鸥,刘洪娟,胡小宣.阿德福韦酯联合聚乙二醇干扰素α-2a治疗高病毒载量慢性乙肝的疗效观察［J］.胃肠病学和肝病学杂志,2013,12(5):456-458.

［2］赖著,严颖,麦丽,等.拉米夫定、恩替卡韦治疗HBeAg阴性慢加急性肝功能衰竭疗效比较［J］.中华传染病杂志,2012,30(6):349-353.

［3］Lok AS,Mcmahon BJ.Chronic hepatitis B：update 2009 ［J］. Hepatology,2009,50(3):661-662.

［4］贾继东, 李兰娟. 慢性乙型肝炎防治指南(2010年版)［J］. 中华内科杂志, 2011, 3(2):1-12.

［5］林孟新,苏智军,郭如意,等.恩替卡韦治疗慢性乙型感染患者外周血T细胞亚群和补体的变化［J］.实用肝脏病杂志,2013,16(4)：354-355.

［6］Walayat S,Ahmed Z,Martin D,et al.Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine［J］.World J Hepatol,2015,7(24):2503-2539.

［7］吴发玲,丁洋,窦晓光,等.聚乙二醇干扰素α-2a联合阿德福韦酯治疗慢性乙型肝炎的Meta分析［J］.实用药物与临床,2012,15(1):4-10.

［8］Zhang J,He S,Li QI,et al.Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy［J］.Virus Res,2013,177(2):156-162.

［9］Abdurakhmanov DT,Otrashevskaya AV.Entecavir in the treatment of chronic hepatitis B:multicenter randomized trials and real clinical practice［J］.Ter Arkh,2014,86（11）:100-104.

［10］Seto WK,Lai CL,Fung J,et al.Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome［J］.J Hepatol，2011,55（3）:522-528.

［11］周文星,吕国良,刘馨.核苷类药物在乙型肝炎后肝硬化治疗中的疗效分析［J］.中国生化药物杂志，2012,33(2):170-172.

［12］张要栋, 徐尧江. 中西医结合对重型慢性乙型肝炎肠道菌群和血浆内毒素的影响［J］. 山西中医, 2016, 32(9):23-25.

［13］Lu H,Wu Z,Xu W,et al.Intestinal microbiota was assessed incirrhotic patients with hepatitis B virus infection［J］.Microb Ecol,2011,61(3):693-703.

［14］Chen Y, Yang F,Lu H,et al.Characterization of fecal microbialcommunities in patients with liver cirrhosis［J］.Hepatology,2011,54(2):562-572.

［15］张小玉,张红梅,杨永锋,等.恩替卡韦抗病毒治疗后老年慢性乙肝患者外周血T淋巴细胞亚群的变化［J］.中华全科医学,2015,13(1):33-35.

［16］张弦,蒋伟,甘建和,等.恩替卡韦治疗慢性乙型肝炎的疗效及其对外周血调节性T细胞水平的影响［J］.山东医药,2016,56(34):42-44.

［17］何伟峰,谭斌.恩替卡韦联合益生菌治疗失代偿期乙肝肝硬化疗效观察［J］.亚太传统医药,2013,9(6):153-154.

［18］林小平,侯卫平,陆军平,等. 恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的临床研究［J］.实用医学杂志,2016,32(6):993-994.

［19］张炤杰. MODS患者肠道菌群紊乱与机体免疫应答、炎症反应的相关性分析［J］. 海南医学院学报, 2017, 23(13):1780-1782.

［20］周冷潇，韩涛，刘保文，等. 肝硬化及肝细胞癌患者肠道微生态组成和结构的初步分析［J］.临床肝胆病杂志，2017,33（9）:1740-1744.

[1]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[2]	QI Linling, LIU Shourong. Research progress of tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 578-582.
[3]	ZHANG Qiang, ZHENG Huajun, LI Quan. Research progress on the treatment of autism spectrum disorders based on gut microbiota intervention [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 475-480.
[4]	YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong. Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
[5]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[6]	TAO Chengjing, LIU Shourong, CHENG Xiaoxian, HU Jiannv, BAI Xiuli, ZHANG Suying, ZHAO Chun, ZUO Zhongbao. Effects of different postpartum withdrawal time of tenofovir on hepatitis B virus markers, virology and biochemical indexes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1146-1152.
[7]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
[8]	SONG Xin, WANG Xue, ZHOU Huanghong, ZHAO Tianyi. Effect of compound glycyrrhizin on the expression and clinical prognosis of antibacterial peptide LL-37 in patients with pigmentary purpuric skin disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 458-463.
[9]	FANG Qing, OU-YANG Dongsheng. Trimethylamine N-oxide and inflammatory disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 318-326.
[10]	ZHU Tingfu, ZOU Chaochun. Clinical effect of Bailing capsule in children with diabetic renal injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 912-915.
[11]	WANG Mengzhi, WEI Yuguang, HUANG Xiaoling. Analysis of rational usage of meropenem in our hospital [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 937-941.
[12]	YU Jinjing, ZHANG Yanping, PAN Jiahua. Effects of early intervention of massage combined with probiotics on neonatal jaundice of later period preterm infants [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 678-681.
[13]	YUAN Gang, HU Airong, HU Yaoren, ZENG Chuanli, ZHU Dedong, SHI Xiaojun. Clinical efficacy and long-term prognosis of entecavir and adefovir dipivoxil in the treatment of compensatory hepatitis B cirrhosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 170-174.
[14]	CHEN Lanfang, QIANG Fuyong, XU Liang. Short-term clinical observation of moderate to severe active rheumatoid arthritis treated with tocilizumab combined with disease modifying antirheumatic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1386-1391.
[15]	DENG Zuyue, HUANG Junjun. Healing effect of Xianling Gubao plus probiotics on osteoporotic fracture rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1126-1131.